The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ESH 2017 | Exportin (XPO1) inhibitors for the treatment of AML
Inhibitors of exportin (XPO1), a nuclear export chaperone, are currently in early clinical trials for acute myeloid leukemia (AML). Speaking from the International Conference on Acute Myeloid Leukaemia 2017 in Estoril, Portugal by the European School of Hematology (ESH), Ramiro Garzon, MD, from the Ohio State University, Columbus, OH, explains why these inhibitors are effective, referencing their effect on both tumor suppressor genes and oncogenes. Dr Garzon also shares preliminary findings from the clinical trials.
